Myelodysplastic Syndromes

Latest News

Pediatrician test results tablet parent child | Image Credit: © nimito - stock.adobe.com
Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition

November 11th 2024

Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, according to researchers.

stem cells | Image Credit: © jarun011 -stock.adobe.com
Study Explores Radiation-Free Transplant Approach for Patients With Dyskeratosis Congenita

November 8th 2024

Blood cells from blood marrow biopsy | image credit: Катерина Євтехова - stock.adobe.com
Patients With MDS Disagree With Physicians About Symptom Frequency

November 2nd 2024

Myeloid malignancy concept, blood cells floating | image credit: Eleni - stock.adobe.com
Phase 1b/2 Study Supports Use of Telaglenastat and Azacytidine in Advanced MDS

October 18th 2024

Cancer cells | Image credit: Sodapeaw - stock.adobe.com
In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment

October 11th 2024

More News

Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma
July 14th 2023

Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma

Rose McNulty
The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.
Elsa Bernard, PhD
July 7th 2023

Validating a New Scoring System in MDS for the Era of Next-Generation Sequencing

Mary Caffrey
A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data.
Image of molecular profiling
December 25th 2022

Distinct Molecular Profiles in Younger vs Older Patients With MDS Identified in New Study

Rose McNulty
The relationship between aging and molecular profiles in myelodysplastic syndromes (MDS) is not well understood, but the findings suggest that different genetic alterations have distinct prognostic implications in different age groups.
blood cells floating around
December 22nd 2022

ICYMI: Top Content From EHA22

AJMC Staff
The 2022 European Hematology Association (EHA22) Congress convened June 9-12, 2022, in Vienna, Austria, and presented cutting-edge findings in hematology, including the potential of artificial intelligence, new treatment combinations in myelofibrosis, and more.
genetic mutations
December 18th 2022

ASXL1 Mutations Associated With Worse Prognosis in MDS and AML

Rose McNulty
A recent meta-analysis found ASXL1 mutations to be independent risk factors for worse overall survival and transformation to acute myeloid leukemia in patients with myelodysplastic syndromes (MDS), as well as worse overall survival in acute myeloid leukemia (AML).
patient with mds
December 12th 2022

Study Identifies Sex-Related Differences in MDS Phenotypes, Genotypes, and Outcomes

Rose McNulty
Authors of the observational cohort study developed and validated novel sex-informed prognostic and genomic scoring systems for patients with myelodysplastic syndrome (MDS).
blood test
December 9th 2022

Phase 3 Trials in High-Risk MDS Highlight Future Directions

Rose McNulty
A recent review emphasizes a need for novel therapies, summarizes current phase 3 clinical trials, and suggests several considerations for future trials in high-risk myelodysplastic syndromes (MDS).
Unmet Needs in Management of Patients With MDS
November 8th 2022

Unmet Needs in Management of Patients With MDS

Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.
Cost-Reduction Strategies in MDS Treatment Pathway
November 8th 2022

Cost-Reduction Strategies in MDS Treatment Pathway

Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.
Oral Therapies in MDS Treatment Strategy
November 1st 2022

Oral Therapies in MDS Treatment Strategy

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.
Utilizing Care Pathways in Treatment of MDS
November 1st 2022

Utilizing Care Pathways in Treatment of MDS

Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.
Payer Considerations for Selecting Optimal MDS Treatment Approach
October 25th 2022

Payer Considerations for Selecting Optimal MDS Treatment Approach

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.
Hypomethylating Agents Impacting MDS Treatment Landscape
October 25th 2022

Hypomethylating Agents Impacting MDS Treatment Landscape

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.
Supportive Care Needs for Patients with MDS
October 18th 2022

Supportive Care Needs for Patients with MDS

Experts discuss the impact of supportive care in the MDS treatment landscape.
Assessing Treatment Goals for Patients with MDS
October 18th 2022

Assessing Treatment Goals for Patients with MDS

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.
Drivers of Health Resource Management in MDS
October 11th 2022

Drivers of Health Resource Management in MDS

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.
Challenges Surrounding Access to Care for Patients With MDS
October 11th 2022

Challenges Surrounding Access to Care for Patients With MDS

Expert panelists explore challenges impacting care access for patients with MDS.
Prognostic Models Optimizing MDS Treatment Pathways
October 4th 2022

Prognostic Models Optimizing MDS Treatment Pathways

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.
Incidence and Prevalence of MDS Across Patient Populations
October 4th 2022

Incidence and Prevalence of MDS Across Patient Populations

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.
MDS Impacting Patient Quality of Life
September 27th 2022

MDS Impacting Patient Quality of Life

Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.
Defining Myelodysplastic Syndrome
September 27th 2022

Defining Myelodysplastic Syndrome

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).
Elli Papaemmanuil, PhD.
June 30th 2022

Dr Elli Papaemmanuil Discusses Molecular Profiling of MDS, Use of Precision Medicine

Matthew Gavidia
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.
Elli Papaemmanuil, PhD.
June 12th 2022

Dr Elli Papaemmanuil Explains Novel Prognostication, Molecular Classification System for MDS

Matthew Gavidia
Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.
Expert on MDS
February 7th 2022

Future Management of Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.
Expert on MDS
February 7th 2022

Interchangeability Between Oral and IV Agents in HR-MDS

Bruce Feinberg, DO Ryan Haumschild, PharmD, MS, MBA Amer Zeidan, MD Tracey Iraca
Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.
Expert on MDS
January 31st 2022

Oral Therapy for HR-MDS: Addressing Patient Adherence

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.
Expert on MDS
January 31st 2022

Practical Considerations for the Use of HMAs in Higher-Risk MDS

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.
Experts on MDS
January 31st 2022

Impact of an Oral HMA on the HR-MDS Treatment Landscape

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.
Expert on MDS
January 24th 2022

Higher-Risk MDS: When to Use HMA Therapy or Lenalidomide

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.
Expert on MDS
January 24th 2022

Goals of Therapy for Patients With Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca
Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo